Japanese collaboration agreement extended to allow final evaluation of performance on clinical samples

Over the past years, AcouSort has worked very closely with the Japanese company’s research team and successfully helped them to optimize their cell separation application required to enable the development of the new diagnostic test. During 2022, AcouSort and the Japanese partner finalized the application optimization of the sample preparation part. In parallel, the Japanese team finalized the development of the assay. The Japanese company has now extended the lease of the AcouWash system to evaluate the complete assay workflow on clinical samples. Once this evaluation is finalized, the Japanese company will start an internal review process to evaluate the business potential and decide whether to initiate a product development project.

The company has been very satisfied with the AcouWash sample preparation, which gives a higher sample quality and is significantly more stable than the centrifugation-based method they initially used.

 

“At AcouSort, we have been very happy with this great collaboration with a world-leading life science company. That the Japanese company has chosen to work with our technology in their assay development, and that the project now has reached the phase where clinical samples will be evaluated, is a great seal of approval. This project is in-line with our long-term strategy; to establish our acoustofluidic technology as the gold standard for providing integrated sample preparation in diagnostic and therapeutic instrumentation. ,” says AcouSort’s CEO Torsten Freltoft.